Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with type 2 diabetes with and without fatty liver

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 7, 2014, Pages G760-G768

  Macfarlane, D P ^a   Raubenheimer, P J ^a   Preston, T ^b   Gray, C D ^c   Bastin, M E ^c   Marshall, I ^c   Iredale, J P ^d   Andrew, R ^a   Walker, B R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SCOTTISH UNIVERSITIES ENVIRONMENTAL RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Fatty acid metabolism; Glucocorticoids; Nonalcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ENZYME INHIBITOR; FATTY ACID; GLUCOCORTICOID RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCEROL; HORMONE ANTAGONIST; HYDROCORTISONE; INSULIN; METYRAPONE; MIFEPRISTONE; STEROID 11BETA MONOOXYGENASE;

ANTAGONISTS AND INHIBITORS; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HUMAN; INDICATOR DILUTION CURVE; LIVER; MALE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENERGY METABOLISM; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; GLYCEROL; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; INDICATOR DILUTION TECHNIQUES; INSULIN; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METYRAPONE; MIDDLE AGED; MIFEPRISTONE; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, GLUCOCORTICOID; SCOTLAND; STEROID 11-BETA-HYDROXYLASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907494427     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00030.2014     Document Type: Article

References (42)

1. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96: 513-523, 1999.
2. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD. Systemic and regional free fatty acid metabolism in Type 2 diabetes. Am J Physiol Endocrinol Metab 280: E1000-E1006, 2001.
3. Blaak EE, Wolffenbuttel BH, Saris WH, Pelsers MM, Wagenmakers AJ. Weight reduction and the impaired plasma-derived free fatty acid oxidation in Type 2 diabetic subjects. J Clin Endocrinol Metab 86: 1638-1644, 2001.
4. Boden G, Shulman GI. Free fatty acids in obesity and Type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32, Suppl 3: 14-23, 2002.
5. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48: 634-642, 2005.
6. Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103: 365-372, 1999.
7. Cushing H. The Pituitary Body and Its Disorders. Philadelphia, PA and London: Lippincott, 1912.
8. Divertie GD, Jensen MD, Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 40: 1228-1232, 1991.
9. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351, 2005.
10. Edgerton DS, Basu R, Ramnanan CJ, Farmer TD, Neal D, Scott M, Jacobson P, Rizza RA, Cherrington AD. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab 298: E1019-E1026, 2010.
11. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134: 424-431, 2008.
12. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with Type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13: 498-504, 2011.
13. Fleck A, Munro HN. The determination of organic nitrogen in biological materials. A review. Clin Chim Acta 11: 2-12, 1965.
14. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55: 628-634, 1983.
15. Garrel DR, Moussali R, De Oliveira A, Lesiege D, Lariviere F. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. J Clin Endocrinol Metab 80: 379-385, 1995.
16. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, DeFronzo RA. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and Type 2 diabetic subjects. Gastroenterology 133: 496-506, 2007.
17. Heikinheimo O, Haukkamaa M, Lahteenmaki P. Distribution of RU 486 and its demethylated metabolites in humans. J Clin Endocrinol Metab 68: 270-275, 1989.
18. Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Porksen N. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45: 49-55, 2002.
19. Isley WL, Harris WS, Miles JM. The effect of high-dose simvastatin on free fatty acid metabolism in patients with Type 2 diabetes mellitus. Metabolism 55: 758-762, 2006.
20. Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, Best R, Brown RW, Edwards CRW, Seckl JR, Mullins JJ. 11-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. Proc Natl Acad Sci USA 94: 14924-14929, 1997.
21. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Jarvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in Type 2 diabetes. Gastroenterology 135: 122-130, 2008.
22. Koutsari C, Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res 47: 1643-1650, 2006.
23. Lemke U, Krones-Herzig A, Berriel DM, Narvekar P, Ziegler A, Vegiopoulos A, Cato AC, Bohl S, Klingmuller U, Screaton RA, Muller-Decker K, Kersten S, Herzig S. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 8: 212-223, 2008.
24. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107: 3441-3446, 2010.
25. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197: 189-204, 2008.
26. Mangos G, Walker BR, Kelly JJ, Lawson J, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic dilatation in the human forearm: towards an explanation for glucocorticoid-induced hypertension. Am J Hypertens 13: 1155-1160, 2000.
27. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease; a feature of the metabolic syndrome. Diabetes 50: 1844-1850, 2001.
28. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
29. Miles JM, Wooldridge D, Grellner WJ, Windsor S, Isley WL, Klein S, Harris WS. Nocturnal and postprandial free fatty acid kinetics in normal and Type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 52: 675-681, 2003.
30. Mittendorfer B, Liem O, Patterson BW, Miles JM, Klein S. What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52: 1641-1648, 2003.
31. Ottosson M, Marin P, Karason K, Elander A, Bjorntorp P. Blockade of the glucocorticoid receptor with RU 486: effects in vitro and in vivo on human adipose tissue lipoprotein lipase activity. Obes Res 3: 233-240, 1995.
32. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101: 7088-7093, 2004.
33. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60: 1500-1510, 2011.
34. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54: 131-138, 1982.
35. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with Type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516-1522, 2010.
36. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Wester-Backa J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87: 3023-3028, 2002.
37. Stefan N, Ramsauer M, Jordan P, Nowotny B, Kantartzis K, Machann J, Hwang JH, Nowotny P, Kahl S, Harreiter J, Hornemann S, Sanyal AJ, Stewart PM, Pfeiffer AF, Kautzky-Willer A, Roden M, Haring HU, Furst-Recktenwald S. Inhibition of 11beta-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 406-416, 2014.
38. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol Endocrinol Metab 276: E977-E989, 1999.
39. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462-E468, 2005.
40. Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F, Walker BR. Effects of peroxisome proliferator-activated receptor-alpha and-gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 92: 1848-1856, 2007.
41. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141: 764-770, 2004.
42. Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD, Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM, Price JF, Strachan MW. The use of ultrasound to diagnose hepatic steatosis in Type 2 diabetes: intra and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol 66: 434-439, 2011